Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05794932
Other study ID # RECHMPL22_0560
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 17, 2023
Est. completion date December 17, 2025

Study information

Verified date May 2023
Source University Hospital, Montpellier
Contact Valérie MONNIN-BARES, MD
Phone +334 67 33 59 91
Email v-monnin@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Post-thrombotic syndrome (PTS) is the most frequently observed chronic complication of deep vein thrombosis (DVT), with an estimated cumulative incidence of 20-50%. Endovascular venous recanalization with angioplasty and stenting of obstructive lesions is the recommended treatment option to reduce or correct the symptoms of DVT. However, its impact on the physical capacity and breathlessness of patients has not been fully demonstrated. The heterogeneous evidences of clinical improvement is probably related to the presence or absence of collateral veins developed in these patients with proximal venous obstruction (iliac or iliofemoral with or without inferior vena cava involvement), which ensure the cardiac venous return. The aim of this study is to compare changes in maximal oxygen uptake after endovascular venous recanalization in DVT patients and to evaluate the hemodynamic, respiratory and muscular improvement induced by the restoration of venous flow in the occluded segments.


Recruitment information / eligibility

Status Recruiting
Enrollment 22
Est. completion date December 17, 2025
Est. primary completion date June 17, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient eligible for endovascular treatment for post-thrombotic syndrome in a chronic context (6 months after the occurrence of thrombosis, without time limit), after validation of the indication during a monthly medical-radiological PCR (St Eloi vascular medicine team and vascular radiologist performing the endovascular treatment) - Age >= 18 years Exclusion Criteria: - Contraindication to the performance of a maximal effort test on a cyclo-ergometer - Refusal of consent after information - Adult protected by law (guardianship, curatorship) - Pregnant or breastfeeding woman - Patient not affiliated to a social security system or not benefiting from such a system

Study Design


Intervention

Diagnostic Test:
Stress test
Diagnostic Test: Maximum effort test (CPET) on a cycloergometer Leg muscle strength assessment Leg muscle mass, composition and water compartments (segmental bioelectrical impedance) Spirometry, arterial blood gaz, NO/CO transfer

Locations

Country Name City State
France Hopital Arnaud de Villeneuve - CHU de Montpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary VO2 max Change in VO2 max is the maximum (max) rate (V) of oxygen (O2) the body is able to use during exercise from baseline to 8 weeks. It is measured in liters of O2 per minute From baseline and 8 weeks
Secondary Maximum aerobic power (in Watts) Maximum aerobic power is measured in watts before and after venous recanalization From baseline and 8 weeks
Secondary Isowork power The isowork power is the power output assessed at the V'O2max before recanalization From baseline and 8 weeks
Secondary Maximal exercise cardiac output (in litres per minute) Maximal exercise cardiac output is the cardiac output assessed by thoracic impedance et peak exercise before and after venous recanalization From baseline and 8 weeks
Secondary Exercise change in Inspiratory capacity (in litres) Exercise change in Inspiratory capacity is the change between rest and peak exercise of the inspiratory capacity (the volume between end-expiratory volume and total lung capacity) before and after venous recanalization From baseline and 8 weeks
Secondary Maximal exercise capillary volume (in millilitres) Maximal exercise capillary volume is the capillary volume at peak exercise assessed by NO/CO transfer before and after venous recanalization From baseline and 8 weeks
Secondary Maximal exercise O2 arterial pressure (PaO2, in mmHg) Maximal exercise O2 arterial pressure is the oxygen partial pressure in the arterial blood, assessed at peak exercise, before and after venous recanalization From baseline and 8 weeks
Secondary Maximal isometric torque during leg extension (in Newton.meters) Maximal isometric strength during leg extension is the maximal torque of the leg extension at 90° knee flexion assessed by a torque sensor before and after venous recanalization From baseline and 8 weeks
Secondary Lower limb extracellular/total water (in %) Lower limb extracellular/total water is the water volume int the body compartments in each lower limb, assessed by a segmental bioelectrical impedancemeter before and after venous recanalization From baseline and 8 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT03613402 - BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes
Recruiting NCT05409976 - The GORE® VIAFORT Vascular Stent IVC Study N/A
Completed NCT03015025 - Pharmacogenetic Dosage Algorithm for Acenocoumarol N/A
Completed NCT03911661 - Fearon Algorithm in Warfarin Patient Self-Management N/A
Recruiting NCT05449808 - Evaluation of Thromboprophylaxis Appropriateness in Hospitalized Medical Patients
Withdrawn NCT05246943 - The Correlation of a D-dimer Testing Protocol With Venous Thromboembolism in Surgical Colorectal Patients
Recruiting NCT01339611 - Education Program for Patients Receiving Oral Anticoagulation N/A
Completed NCT04367831 - Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 Phase 4
Recruiting NCT05711173 - Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE) N/A
Completed NCT04824118 - Clotting Parameters After Medical Abortion
Withdrawn NCT01810237 - Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy N/A
Recruiting NCT05489588 - The GORE® VIAFORT Vascular Stent Iliofemoral Study N/A
Completed NCT05087108 - Evaluation of the OsciPulse Rapid Cycling Compression Device Effects on Venous Blood Flow Early Phase 1
Terminated NCT04128956 - Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS Phase 2
Completed NCT04439383 - Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients
Not yet recruiting NCT06452342 - TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study Phase 4
Recruiting NCT06087952 - Leiden Thrombosis Recurrence Risk Prevention N/A
Completed NCT05515120 - Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events Phase 2/Phase 3
Completed NCT03611894 - Comparison of the Radiological Pattern Between the Cerebral Stroke of Arterial and Venous Origin
Completed NCT03835780 - The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study